ArticleParasites & vectors2025
Efficacy evaluation of lotilaner (Credelio™) in experimentally induced Otodectes cynotis infestations in cats.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral lotilaner in 21 cats with naturally acquired harvest mite infestation.Journal of feline medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ear mite, Otodectes cynotis, is pathogenic, highly contagious and a global cause of otitis externa and pruritus in cats and dogs. The present study evaluated the efficacy of a single oral application of lotilaner flavoured chewable tablets for cats (Credelio™; Elanco, Greenfield, IN, USA) in cats experimentally infested with O. cynotis.
methodsSixteen adult cats were experimentally infested with O. cynotis and confirmed to be mite positive by otoscopic examination. Infested cats were randomly assigned to one of two study groups. On day 0, a group of eight cats was treated once with Credelio™ at 7.0-11.8 mg lotilaner/kg body weight (i.e. at the lower end of the recommended dose range [6-24 mg/kg]), while in the control group eight cats were sham-dosed. All cats were dosed in a fed state. Otoscopic examinations for scoring the number of live mites and the amount of debris/cerumen were performed post treatment (p.t) on days 14 and 28. Ear flushing and microscopic viable mite counts were performed on day 28.
resultsA single oral dose of Credelio™ on day 0 resulted in a 99.6% reduction in O. cynotis geometric mean mite counts in the Credelio™-treated study group on day 28 recovered by ear flushing. Otoscopic live ear mite count scores on days 14 and 28 did not detect any mites in the Credelio™-treated group. In contrast to this 100% improvement, in the control group an improvement of otoscopic live mite scores was recorded in 25% (day 14) and 12.5% (day 28) of the cats, respectively. Additionally, a comparison of the debris scores to baseline data on day - 2 showed an improvement in 75% of the Credelio™-treated cats on day 14 and in 87.5% on day 28 and no or limited improvement (0% on day 14 and 12.5% on day 28) in the control group animals.
conclusionsThe results of this study demonstrated that a single application of Credelio™ chewable tablets for cats at the lower end of the recommended dose range was highly efficacious (99.6%) in eliminating experimentally induced O. cynotis infestations and greatly improved clinical signs of otocariosis in cats by 28 days p.t.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.